Clinical Trial Update: 68 Ga-PSMA for High Risk Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating 68 Ga-PSMA for high-risk prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68 Ga-PSMA (prostate-specific membrane antigen ligand labeled with gallium-68)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Prostate Cancer, High Risk | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-29